Dr. Guan-Huei Lee graduated from the National University of Singapore (NUS), and completed his advance specialist training in Gastroenterology in 2009. He received further training a clinical fellow at the Institute of Liver Studies, King’s College Hospital, London, focusing on liver intensive care. He received his PhD from NUS in 2014. He was awarded Fellowship of the Royal College of Physicians of Edinburgh in 2015.
Dr. Lee has helped to strengthen the clinical and research capabilities of the Division of Gastroenterology & Hepatology, National University Hospital (NUH), particularly in the management of liver failure and liver transplantation. He is serving dual role as Deputy Head, Division of Gastroenterology & Hepatology, and Medical Director, Adult Liver Transplantation Programme, National University Centre for Organ Transplantation (NUCOT).
Dr. Lee’s research work centers on the application of innovations in technology and biomedical science to the field of Hepatology. His current work focuses on developing novel targets to achieve functional cure of chronic hepatitis B. His other research interest includes liver failure, liver cancer, fatty liver and chronic hepatitis E. He has published multiple peer-reviewed research articles in such top-tier journals as the Gastroenterology, Gut, and Molecular & Cellular Biology. His research work has been presented at the major meetings of such organisations as the APASL, EASL, ILTS, and AASLD. He is an investigator of several competitive research grants including the Translational & Clinical Research Flagship (TCR) Programme grant, Clinician Scientist-Individual Research Grant (CS-IRG) and was awarded the NMRC Clinician Scientist Award (CSA).
Personal hobbies and interests: Reading, Tennis, Photography, Hiking and Mountain Climbing
1. Lee, GH., Chen, D.H. & Lim, SG. Future Therapy for Hepatitis B Virus: Role of Nucleos(t)ide Analogues and Pegylated Interferon Therapy. Curr Hepatology Rep (2016) 15: 230.
2. Phyo WW, Soh AY, Lim SG, Lee GH. Search for a cure for chronic hepatitis B infection: How close are we? World J Hepatol. 2015 May 28;7(9):1272-81.
3. McPhail MJW, Shawcross DL, Abeles RD, et al. Improving survival and predicting outcome in patients with cirrhosis with organ failure: a decade of experience in liver intensive care. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1353-1360.e8.
4. Francisco JC, Dai Q, Luo Z, et al. Transcriptional elongation control of the HBV cccDNA transcription by Super Elongation Complex (SEC) and BRD4. Mol Cell Biol. 2017 Sep 12;37(19).
5. Lee GH, Inoue M, Chong RH, Toh J, Wee SY, Loh KS, Lim SG. Pyrosequencing method for sensitive detection of HBV drug resistance mutations. J Med Virol. 2018 Feb 28.
6. Zhao Y et al. Development of a new patient-derived xenograft humanized mouse model to study human specific tumor microenvironment and immunotherapy. Gut. 2018 Mar 30.
7. Zhu YO, Aw P, Aung MM, Lee HK, Hibberd M, Lee GH. Patterns of mutation within an emerging endemic lineage of HEV-3a. J Viral Hepat. 2019 Jan;26(1):191-198.
8. Tan EX, Wang MX, Pang J, Lee GH. Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review. World J Gastroenterol. 2020 Jan 14;26(2):219-245.
9. Duseja A, De A, Taneja S, et al. (APASL ACLF Research Consortium). Impact of Metabolic Risk Factors on the Severity and Outcome of Patients with Alcohol Associated Acute-on-Chronic Liver Failure. Liver Int. 2020 Sep 24.
10. Lim SG, Phyo WW, Ling JZJ, et al. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg). Aliment Pharmacol Ther. 2020 Nov 7.